While you’re waiting for quarterly reports to tell you what’s happening in your market, your competitors already know. They’re tracking...

Investors in 2025 aren’t just backing biotech science—they’re judging execution. CEOs who can’t show scaling signals—operational rhythm, cross-team clarity, and a real scalability narrative—risk burning credibility, not just capital. This memo breaks down the three signals biotech leaders must master to win trust and funding.

If you’ve been searching for months to hire a scientist, regulatory lead, or business development partner — but keep getting average or...